Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1983 2
1984 4
1987 1
1988 2
1989 11
1990 8
1991 13
1992 3
1993 5
1994 7
1995 6
1996 10
1997 5
1998 4
1999 7
2000 6
2001 11
2002 7
2003 10
2004 7
2005 6
2006 5
2007 10
2008 6
2009 11
2010 10
2011 10
2012 17
2013 16
2014 18
2015 13
2016 19
2017 15
2018 18
2019 16
2020 20
2021 18
2022 22
2023 15
2024 11
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

382 results

Results by year

Filters applied: . Clear all
Page 1
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Among authors: roselli m. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Free article. Clinical Trial.
HIF2α, Hepcidin and their crosstalk as tumour-promoting signalling.
Formica V, Riondino S, Morelli C, Guerriero S, D'Amore F, Di Grazia A, Del Vecchio Blanco G, Sica G, Arkenau HT, Monteleone G, Roselli M. Formica V, et al. Among authors: roselli m. Br J Cancer. 2023 Aug;129(2):222-236. doi: 10.1038/s41416-023-02266-2. Epub 2023 Apr 20. Br J Cancer. 2023. PMID: 37081189 Free PMC article. Review.
Obesity-driven inflammation and colorectal cancer.
Vazzana N, Riondino S, Toto V, Guadagni F, Roselli M, Davi G, Ferroni P. Vazzana N, et al. Among authors: roselli m. Curr Med Chem. 2012;19(34):5837-53. doi: 10.2174/092986712804143349. Curr Med Chem. 2012. PMID: 23033947 Review.
PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials.
Formica V, Morelli C, Fornaro L, Riondino S, Rofei M, Fontana E, Smyth EC, Roselli M, Arkenau HT. Formica V, et al. Among authors: roselli m. ESMO Open. 2024 Nov;9(11):103967. doi: 10.1016/j.esmoop.2024.103967. Epub 2024 Nov 13. ESMO Open. 2024. PMID: 39541621 Free PMC article.
Monoclonal antibodies in gastrointestinal cancers.
Bronte G, Cicero G, Cusenza S, Galvano A, Musso E, Rizzo S, Sortino G, Roselli M, Bazan V, Fiorentino E, Russo A. Bronte G, et al. Among authors: roselli m. Expert Opin Biol Ther. 2013 Jun;13(6):889-900. doi: 10.1517/14712598.2013.774367. Epub 2013 Feb 27. Expert Opin Biol Ther. 2013. PMID: 23441760 Free article. Review.
382 results